4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Uveitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 110 ongoing clinical trials involving Uveitis
Of the 110 trials,40 trials are in Phase III
Furthermore, 33 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Uveitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Uveitis, an Ophthalmology condition. The largest number of ongoing clinical trials for Uveitis is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Uveitis-related drug trials.

Tianjin Medical University and Peking Union Medical College Hospital: The leading ongoing Uveitis related clinical trial sponsors

Tianjin Medical University and Peking Union Medical College Hospital are the top sponsors for Uveitis-related ongoing clinical trials.

The Johns Hopkins Bloomberg School of Public Health, L.V. Prasad Eye Institute, The Cleveland Clinic Foundation and EyePoint Pharmaceuticals Inc are among other notable clinical trial sponsors involved in Uveitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Uveitis

Adalimumab (Humira), Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) and Infliximab biosimilar (Remsima, Inflectra, Flixceli, Emisima, Remsima SC, Infliximab BS) are among the key marketed drugs involving Uveitis.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as injection for subcutaneous route of administration. Adalimumab was first approved in 2002 and is marketed globally in the US, UK, China, Japan, France and Germany by several prominent pharma giants including AbbVie Inc.

Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) is a purified preparation of the adrenocorticotropic hormone (ACTH) obtained from porcine pituitary. It functions via Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Agonist; Melanocortin Receptor 3 (MC3R) Agonist; Melanocortin Receptor 4 (MC4R) Agonist; Melanocortin Receptor 5 (MC 2 or MC5R) Agonist; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Agonist mechanism of action. Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) is formulated as injection gel for intramuscular and subcutaneous route of administration and powder for solution for intravenous, intramuscular and subcutaneous routes of administration. Corticotropin, Repository Corticotropin was first approved in 1950 and is marketed in the US and New Zealand by Mallinckrodt LLC and Sanofi-Aventis New Zealand Ltd.